30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Immunovant Inc (IMVT)

Track

Over the last 90 days, Immunovant Inc. has seen significant insider selling, with a net value of -$9.61 million. Executives contributed -$2.17 million to this net sell-off. Notable transactions include large sell orders from Andrew J. Fromkin and Atul Pande. The company's stock has performed strongly, up 41.7% in 90 days, nearing its 52-week high.
Stock chart
Ticker: IMVT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Van Tuyl Christopher
Chief Legal Officer
2 sales — total 200,000 USD
Sale 18 Jun 2026
Value US$1,783,551.06 | Price 310.28 | Shares 91,584
Sale 18 Jun 2026
Value US$248,125.82 | Price 496.14 | Shares 98,417
Planned sale 15 Jun 2026
Value US$3,822,099.74 | Price 425.02 | Shares 58,418
Proposed sale 15 Jun 2026
Value US$100,000.00 | Price 33.62 | Shares 1,000
Sale 28 May 2026
Value US$7,063,306.08 | Price 33.56 | Shares 210,468
Sale 28 May 2026
Value US$374,805.12 | Price 32.64 | Shares 11,483
Proposed sale 28 May 2026
Value US$7,438,709.96 | Price 33.52 | Shares 221,951
Sale 20 May 2026
Value US$55,949.10 | Price 32.95 | Shares 1,698
Sale 20 May 2026
Value US$37,551.20 | Price 32.15 | Shares 1,168
Sale 20 May 2026
Value US$7,572.09 | Price 30.41 | Shares 249
Planned sale 20 May 2026
Value US$192,000.00 | Price 32.00 | Shares 6,000
Proposed sale 20 May 2026
Value US$157,740.00 | Price 26.29 | Shares 6,000
Planned sale 1 May 2026
Value US$67,979.34 | Price 27.17 | Shares 2,502
Proposed sale 1 May 2026
Value US$67,916.79 | Price 27.14 | Shares 2,502
Sale 23 Apr 2026
Value US$763,011.20 | Price 29.62 | Shares 25,760
Sale 23 Apr 2026
Value US$81,573.48 | Price 29.62 | Shares 2,754
Sale 8 Apr 2026
Value US$128,246.95 | Price 24.83 | Shares 5,165
Sale 8 Apr 2026
Value US$216,567.26 | Price 24.83 | Shares 8,722
Sale 8 Apr 2026
Value US$216,567.26 | Price 24.83 | Shares 8,722
Sale 8 Apr 2026
Value US$37,691.94 | Price 24.83 | Shares 1,518
Sale 8 Apr 2026
Value US$213,885.62 | Price 24.83 | Shares 8,614
Sale 2 Apr 2026
Value US$34,661.40 | Price 24.60 | Shares 1,409
Sale 2 Apr 2026
Value US$308,192.80 | Price 24.04 | Shares 12,820
Sale 18 Mar 2026
Value US$71,838.69 | Price 24.97 | Shares 2,877
Sale 25 Feb 2026
Value US$27,223.80 | Price 28.90 | Shares 942
Sale 25 Feb 2026
Value US$24,189.44 | Price 28.16 | Shares 859
Sale 25 Feb 2026
Value US$38,770.26 | Price 26.98 | Shares 1,437
Proposed sale 10 Feb 2026
Value US$155,237.00 | Price 26.77 | Shares 5,800
Sale 21 Jan 2026
Value US$51,461.31 | Price 26.03 | Shares 1,977
Sale 7 Jan 2026
Value US$1,480.60 | Price 26.92 | Shares 55
Sale 7 Jan 2026
Value US$30,433.48 | Price 26.51 | Shares 1,148
Sale 18 Dec 2025
Value US$62,535.92 | Price 27.38 | Shares 2,284
Sale 18 Dec 2025
Value US$228,406.62 | Price 26.78 | Shares 8,529
Buy 12 Dec 2025
Value US$349,999,986.00 | Price 21.00 | Shares 16,666,666
Planned sale 1 Dec 2025
Value US$69,407.10 | Price 23.95 | Shares 2,898
Planned sale 1 Dec 2025
Value US$447,782.14 | Price 23.14 | Shares 19,351
Planned sale 1 Dec 2025
Value US$45,739.64 | Price 23.96 | Shares 1,909
Planned sale 1 Dec 2025
Value US$302,925.74 | Price 23.14 | Shares 13,091
Proposed sale 1 Dec 2025
Value US$537,313.35 | Price 24.15 | Shares 22,249
Proposed sale 1 Dec 2025
Value US$362,250.00 | Price 24.15 | Shares 15,000
Proposed sale 26 Nov 2025
Value US$1,185,045.00 | Price 23.70 | Shares 50,000
Proposed sale 25 Nov 2025
Value US$2,428,803.72 | Price 23.38 | Shares 103,897
Sale 20 Nov 2025
Value US$56,928.75 | Price 23.97 | Shares 2,375
Sale 20 Nov 2025
Value US$241,308.54 | Price 23.54 | Shares 10,251
Sale 22 Oct 2025
Value US$49,382.85 | Price 19.03 | Shares 2,595
Sale 22 Oct 2025
Value US$47,955.60 | Price 19.03 | Shares 2,520
Sale 8 Oct 2025
Value US$25,835.50 | Price 16.30 | Shares 1,585
Sale 8 Oct 2025
Value US$20,733.60 | Price 16.30 | Shares 1,272
Sale 23 Jul 2025
Value US$50,910.75 | Price 18.15 | Shares 2,805
Sale 23 Jul 2025
Value US$43,287.75 | Price 18.15 | Shares 2,385
Sale 9 Jul 2025
Value US$26,187.56 | Price 17.24 | Shares 1,519
Sale 9 Jul 2025
Value US$19,998.40 | Price 17.24 | Shares 1,160
Proposed sale 25 Jun 2025
Value US$474,861.00 | Price 15.83 | Shares 30,000
Proposed sale 13 Jun 2025
Value US$778,490.00 | Price 15.57 | Shares 50,000
Proposed sale 3 Jun 2025
Value US$1,248,616.00 | Price 15.61 | Shares 80,000
Proposed sale 21 May 2025
Value US$318,047.32 | Price 14.58 | Shares 21,812
Proposed sale 19 May 2025
Value US$410,907.75 | Price 14.58 | Shares 28,188
Sale 23 Apr 2025
Value US$28,470.75 | Price 14.79 | Shares 1,925
Sale 23 Apr 2025
Value US$34,741.71 | Price 14.79 | Shares 2,349
Sale 16 Apr 2025
Value US$44,565.77 | Price 14.89 | Shares 2,993
Sale 16 Apr 2025
Value US$123,899.69 | Price 14.89 | Shares 8,321
Sale 9 Apr 2025
Value US$52,609.50 | Price 12.99 | Shares 4,050
Sale 9 Apr 2025
Value US$91,098.87 | Price 12.99 | Shares 7,013
Sale 9 Apr 2025
Value US$80,135.31 | Price 12.99 | Shares 6,169
Sale 9 Apr 2025
Value US$65,001.96 | Price 12.99 | Shares 5,004
Sale 9 Apr 2025
Value US$364,941.06 | Price 12.99 | Shares 28,094
Planned sale 7 Mar 2025
Value US$27,624.64 | Price 19.96 | Shares 1,384
Planned sale 7 Mar 2025
Value US$129,144.32 | Price 19.52 | Shares 6,616
Proposed sale 7 Mar 2025
Value US$156,160.00 | Price 19.52 | Shares 8,000
Sale 19 Feb 2025
Value US$322,057.54 | Price 20.86 | Shares 15,439
Sale 19 Feb 2025
Value US$42,867.30 | Price 20.86 | Shares 2,055
Sale 19 Feb 2025
Value US$58,700.04 | Price 20.86 | Shares 2,814
Proposed sale 14 Feb 2025
Value US$1,406,756.94 | Price 20.16 | Shares 69,763
Proposed sale 11 Feb 2025
Value US$570,437.29 | Price 19.54 | Shares 29,196
Sale 22 Jan 2025
Value US$62,678.63 | Price 23.59 | Shares 2,657
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-22 2026-06-18 S Sale
2.0
Van Tuyl Christopher

Chief Legal Officer

Officer
91,584 +40.8%
310.28
US$1,783,551 		91,584 +40.8% 310.28 US$1,783,551
2026-06-22 2026-06-18 S Sale
2.0
Van Tuyl Christopher

Chief Legal Officer

Officer
98,417 +11.8%
496.14
US$248,126 		98,417 +11.8% 496.14 US$248,126
2026-06-16 2026-06-15 PlS Planned sale
3.4
Pande Atul
Non-Executive Director
58,418 -16.4%
425.02
US$3,822,100 		58,418 -16.4% 425.02 US$3,822,100
2026-06-15 2026-06-15 PrS Proposed sale
3.4
Atul Pande

Director

Non-Executive Director
1,000
33.62
US$100,000 		1,000 33.62 US$100,000
2026-05-29 2026-05-28 S Sale
Fromkin Andrew J.
Non-Executive Director
210,468 -73.9%
33.56
US$7,063,306 		210,468 -73.9% 33.56 US$7,063,306
2026-05-29 2026-05-28 S Sale
Fromkin Andrew J.
Non-Executive Director
11,483 -3.9%
32.64
US$374,805 		11,483 -3.9% 32.64 US$374,805
2026-05-28 2026-05-28 PrS Proposed sale
ANDREW J FROMKIN

Director

Non-Executive Director
221,951
33.52
US$7,438,710 		221,951 33.52 US$7,438,710
2026-05-22 2026-05-20 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
1,698 -0.7%
32.95
US$55,949 		1,698 -0.7% 32.95 US$55,949
2026-05-22 2026-05-20 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
1,168 -0.5%
32.15
US$37,551 		1,168 -0.5% 32.15 US$37,551
2026-05-22 2026-05-20 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
249 -0.1%
30.41
US$7,572 		249 -0.1% 30.41 US$7,572
2026-05-20 2026-05-20 PlS Planned sale
3.4
Pande Atul
Non-Executive Director
6,000 -4.9%
32.00
US$192,000 		6,000 -4.9% 32.00 US$192,000
2026-05-20 2026-05-20 PrS Proposed sale
3.4
Atul Pande

Director

Non-Executive Director
6,000
26.29
US$157,740 		6,000 26.29 US$157,740
2026-05-01 2026-05-01 PlS Planned sale
Susman Robert Graham
Non-Executive Director
2,502 -6.4%
27.17
US$67,979 		2,502 -6.4% 27.17 US$67,979
2026-05-01 2026-05-01 PrS Proposed sale
ROBERT G SUSMAN

Director

Non-Executive Director
2,502
27.14
US$67,917 		2,502 27.14 US$67,917
2026-04-24 2026-04-23 S Sale
Girao Tiago

Chief Financial Officer

Officer
25,760 -9.4%
29.62
US$763,011 		25,760 -9.4% 29.62 US$763,011
2026-04-24 2026-04-23 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
2,754 -1.1%
29.62
US$81,573 		2,754 -1.1% 29.62 US$81,573
2026-04-10 2026-04-08 S Sale
2.0
Van Tuyl Christopher

Chief Legal Officer

Officer
5,165 -2.7%
24.83
US$128,247 		5,165 -2.7% 24.83 US$128,247
2026-04-10 2026-04-08 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
8,722 -3.4%
24.83
US$216,567 		8,722 -3.4% 24.83 US$216,567
2026-04-10 2026-04-08 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
8,722 -3.4%
24.83
US$216,567 		8,722 -3.4% 24.83 US$216,567
2026-04-10 2026-04-08 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
1,518 -0.6%
24.83
US$37,692 		1,518 -0.6% 24.83 US$37,692
2026-04-10 2026-04-08 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
8,614 -3.3%
24.83
US$213,886 		8,614 -3.3% 24.83 US$213,886
2026-04-03 2026-04-02 S Sale
2.2
Venker Eric

Chief Executive Officer

Executive Director
1,409 -6.7%
24.60
US$34,661 		1,409 -6.7% 24.60 US$34,661
2026-04-03 2026-04-02 S Sale
2.2
Venker Eric

Chief Executive Officer

Executive Director
12,820 -37.9%
24.04
US$308,193 		12,820 -37.9% 24.04 US$308,193
2026-03-20 2026-03-18 S Sale
2.0
Van Tuyl Christopher

Chief Legal Officer

Officer
2,877 -1.9%
24.97
US$71,839 		2,877 -1.9% 24.97 US$71,839
2026-02-27 2026-02-25 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
942 -0.6%
28.90
US$27,224 		942 -0.6% 28.90 US$27,224
2026-02-27 2026-02-25 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
859 -0.5%
28.16
US$24,189 		859 -0.5% 28.16 US$24,189
2026-02-27 2026-02-25 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
1,437 -0.8%
26.98
US$38,770 		1,437 -0.8% 26.98 US$38,770
2026-02-10 2026-02-10 PrS Proposed sale
3.3
MICHAEL GEFFNER

Officer

Officer
5,800
26.77
US$155,237 		5,800 26.77 US$155,237
2026-01-23 2026-01-21 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
1,977 -1.0%
26.03
US$51,461 		1,977 -1.0% 26.03 US$51,461
2026-01-09 2026-01-07 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
55 -0.0%
26.92
US$1,481 		55 -0.0% 26.92 US$1,481
2026-01-09 2026-01-07 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
1,148 -0.6%
26.51
US$30,433 		1,148 -0.6% 26.51 US$30,433
2025-12-19 2025-12-18 S Sale
2.0
Van Tuyl Christopher

Chief Legal Officer

Officer
2,284 -1.5%
27.38
US$62,536 		2,284 -1.5% 27.38 US$62,536
2025-12-19 2025-12-18 S Sale
2.0
Van Tuyl Christopher

Chief Legal Officer

Officer
8,529 -5.3%
26.78
US$228,407 		8,529 -5.3% 26.78 US$228,407
2025-12-12 2025-12-12 B Purchase
1.9
Roivant Sciences Ltd.
Non-Executive Director Large shareholder
16,666,666 +17.2%
21.00
US$349,999,986 		16,666,666 +17.2% 21.00 US$349,999,986
2025-12-03 2025-12-01 PlS Planned sale
Fromkin Andrew J.
Non-Executive Director
2,898 -3.3%
23.95
US$69,407 		2,898 -3.3% 23.95 US$69,407
2025-12-03 2025-12-01 PlS Planned sale
Fromkin Andrew J.
Non-Executive Director
19,351 -17.9%
23.14
US$447,782 		19,351 -17.9% 23.14 US$447,782
2025-12-03 2025-12-01 PlS Planned sale
Hughes Douglas J.
Non-Executive Director
1,909 -1.6%
23.96
US$45,740 		1,909 -1.6% 23.96 US$45,740
2025-12-03 2025-12-01 PlS Planned sale
Hughes Douglas J.
Non-Executive Director
13,091 -9.6%
23.14
US$302,926 		13,091 -9.6% 23.14 US$302,926
2025-12-01 2025-12-01 PrS Proposed sale
ANDREW J FROMKIN

Director

Non-Executive Director
22,249
24.15
US$537,313 		22,249 24.15 US$537,313
2025-12-01 2025-12-01 PrS Proposed sale
DOUGLAS HUGHES

Director

Non-Executive Director
15,000
24.15
US$362,250 		15,000 24.15 US$362,250
2025-11-26 2025-11-26 PrS Proposed sale
3.3
MICHAEL GEFFNER

Officer

Officer
50,000
23.70
US$1,185,045 		50,000 23.70 US$1,185,045
2025-11-25 2025-11-25 PrS Proposed sale
3.3
MICHAEL GEFFNER

Officer

Officer
103,897
23.38
US$2,428,804 		103,897 23.38 US$2,428,804
2025-11-21 2025-11-20 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
2,375 -1.4%
23.97
US$56,929 		2,375 -1.4% 23.97 US$56,929
2025-11-21 2025-11-20 S Sale
1.8
Gloria Melanie

Chief Operating Officer

Officer
10,251 -5.5%
23.54
US$241,309 		10,251 -5.5% 23.54 US$241,309
2025-10-24 2025-10-22 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
2,595 -1.2%
19.03
US$49,383 		2,595 -1.2% 19.03 US$49,383
2025-10-24 2025-10-22 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
2,520 -1.2%
19.03
US$47,956 		2,520 -1.2% 19.03 US$47,956
2025-10-10 2025-10-08 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
1,585 -0.8%
16.30
US$25,836 		1,585 -0.8% 16.30 US$25,836
2025-10-10 2025-10-08 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
1,272 -0.6%
16.30
US$20,734 		1,272 -0.6% 16.30 US$20,734
2025-07-25 2025-07-23 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
2,805 -1.4%
18.15
US$50,911 		2,805 -1.4% 18.15 US$50,911
2025-07-25 2025-07-23 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
2,385 -1.1%
18.15
US$43,288 		2,385 -1.1% 18.15 US$43,288
2025-07-11 2025-07-09 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
1,519 -0.7%
17.24
US$26,188 		1,519 -0.7% 17.24 US$26,188
2025-07-11 2025-07-09 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
1,160 -0.5%
17.24
US$19,998 		1,160 -0.5% 17.24 US$19,998
2025-06-25 2025-06-25 PrS Proposed sale
3.2
WILLIAM MACIAS

Officer

Officer
30,000
15.83
US$474,861 		30,000 15.83 US$474,861
2025-06-13 2025-06-13 PrS Proposed sale
3.2
WILLIAM MACIAS

Officer

Officer
50,000
15.57
US$778,490 		50,000 15.57 US$778,490
2025-06-03 2025-06-03 PrS Proposed sale
3.2
WILLIAM MACIAS

Officer

Officer
80,000
15.61
US$1,248,616 		80,000 15.61 US$1,248,616
2025-05-21 2025-05-21 PrS Proposed sale
GEORGE V MIGAUSKY

Former Director

Non-Executive Director
21,812
14.58
US$318,047 		21,812 14.58 US$318,047
2025-05-19 2025-05-19 PrS Proposed sale
GEORGE V MIGAUSKY

Former Director

Non-Executive Director
28,188
14.58
US$410,908 		28,188 14.58 US$410,908
2025-04-25 2025-04-23 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
1,925 -0.9%
14.79
US$28,471 		1,925 -0.9% 14.79 US$28,471
2025-04-25 2025-04-23 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
2,349 -1.0%
14.79
US$34,742 		2,349 -1.0% 14.79 US$34,742
2025-04-17 2025-04-16 S Sale
3.1
Barnett Eva Renee

Chief Financial Officer

Officer
2,993 -0.7%
14.89
US$44,566 		2,993 -0.7% 14.89 US$44,566
2025-04-17 2025-04-16 S Sale
2.4
Salzmann Peter

Chief Executive Officer

Executive Director
8,321 -0.7%
14.89
US$123,900 		8,321 -0.7% 14.89 US$123,900
2025-04-11 2025-04-09 S Sale
3.1
Barnett Eva Renee

Chief Financial Officer

Officer
4,050 -1.0%
12.99
US$52,610 		4,050 -1.0% 12.99 US$52,610
2025-04-11 2025-04-09 S Sale
3.1
Barnett Eva Renee

Chief Financial Officer

Officer
7,013 -1.7%
12.99
US$91,099 		7,013 -1.7% 12.99 US$91,099
2025-04-11 2025-04-09 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
6,169 -2.6%
12.99
US$80,135 		6,169 -2.6% 12.99 US$80,135
2025-04-11 2025-04-09 S Sale
2.7
Stout Jay S

Chief Technology Officer

Officer
5,004 -2.3%
12.99
US$65,002 		5,004 -2.3% 12.99 US$65,002
2025-04-11 2025-04-09 S Sale
2.4
Salzmann Peter

Chief Executive Officer

Executive Director
28,094 -2.3%
12.99
US$364,941 		28,094 -2.3% 12.99 US$364,941
2025-03-11 2025-03-07 PlS Planned sale
Fromkin Andrew J.
Non-Executive Director
1,384 -1.5%
19.96
US$27,625 		1,384 -1.5% 19.96 US$27,625
2025-03-11 2025-03-07 PlS Planned sale
Fromkin Andrew J.
Non-Executive Director
6,616 -6.6%
19.52
US$129,144 		6,616 -6.6% 19.52 US$129,144
2025-03-07 2025-03-07 PrS Proposed sale
ANDREW J FROMKIN

Director

Non-Executive Director
8,000
19.52
US$156,160 		8,000 19.52 US$156,160
2025-02-21 2025-02-19 S Sale
2.4
Salzmann Peter

Chief Executive Officer

Executive Director
15,439 -1.6%
20.86
US$322,058 		15,439 -1.6% 20.86 US$322,058
2025-02-21 2025-02-19 S Sale
3.2
Macias William L.

Chief Medical Officer

Officer
2,055 -0.6%
20.86
US$42,867 		2,055 -0.6% 20.86 US$42,867
2025-02-21 2025-02-19 S Sale
3.1
Barnett Eva Renee

Chief Financial Officer

Officer
2,814 -0.9%
20.86
US$58,700 		2,814 -0.9% 20.86 US$58,700
2025-02-14 2025-02-14 PrS Proposed sale
2.9
MARK S LEVINE

Former Affiliate
69,763
20.16
US$1,406,757 		69,763 20.16 US$1,406,757
2025-02-11 2025-02-11 PrS Proposed sale
2.9
MARK S LEVINE

Former Affiliate
29,196
19.54
US$570,437 		29,196 19.54 US$570,437
2025-01-24 2025-01-22 S Sale
3.3
Geffner Michael

Chief Medical Officer

Officer
2,657 -2.0%
23.59
US$62,679 		2,657 -2.0% 23.59 US$62,679
Explore more

More insider trading research around Immunovant Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America